Palvella Therapeutics (PVLA) Tax Provisions (2014 - 2025)
Palvella Therapeutics (PVLA) posted quarterly Tax Provisions of -$164000.0 for Q4 2018, down 213.89% year-over-year from $144000.0 in Q4 2017, and down 10.81% quarter-over-quarter from -$148000.0 in Q2 2018.
Palvella Therapeutics (PVLA) Tax Provisions (2014 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Tax Provisions for 4 consecutive years, with -$164000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Tax Provisions fell 213.89% year-over-year to -$164000.0; the TTM figure through Sep 2019 stood at -$164000.0 (down 4000.0% YoY), while the FY2020 annual figure was $164000.0, changed N/A from the prior year.
- Tax Provisions retreated to -$164000.0 in Q4 2018 per PVLA's latest filing, from -$148000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $814000.0 in Q2 2017 and bottomed at -$164000.0 in Q4 2018.
- Historically, Tax Provisions has averaged $99581.2 across 4 years, with a median of $20211.5 in 2014.
- Annual changes were most pronounced in 2015 — Tax Provisions soared 224772.22% — and 2018, when it plunged 213.89%.
- Palvella Therapeutics' Tax Provisions stood at -$18.0 in 2014, then jumped by 908016.67% to $163425.0 in 2015, then declined by 11.89% to $144000.0 in 2017, then slumped by 213.89% to -$164000.0 in 2018.
- Business Quant data shows PVLA's Tax Provisions at -$164000.0 in Q4 2018, -$148000.0 in Q2 2018, and $144000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.76 Mn |
| Dec 31, 2024 | -3.66 Mn |
| Dec 31, 2018 | -164,000.00 |
| Jun 30, 2018 | -148,000.00 |
| Dec 31, 2017 | 144,000.00 |
| Sep 30, 2017 | 146,000.00 |
| Jun 30, 2017 | 814,000.00 |
| Dec 31, 2015 | 163,425.00 |
| Sep 30, 2015 | 40,441.00 |
| Sep 30, 2014 | -18.00 |
| Jun 30, 2014 | -18.00 |
| Mar 31, 2014 | -18.00 |